BFEC
TGTX icon

Benjamin F. Edwards & Company’s TG Therapeutics TGTX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$16K Hold
900
– – ﹤0.01% 1597
2024
Q1 		$14K Hold
900
– – ﹤0.01% 1622
2023
Q4 		$15K Hold
900
– – ﹤0.01% 1561
2023
Q3 		$8K Hold
900
– – ﹤0.01% 1456
2023
Q2 		$22K Hold
900
– – ﹤0.01% 1257
2023
Q1 		$14K Hold
900
– – ﹤0.01% 1349
2022
Q4 		$11K Hold
900
– – ﹤0.01% 1411
2022
Q3 		$5K Hold
900
– – ﹤0.01% 1569
2022
Q2 		$4K Sell
900
-1,000
-53% -$6.24K ﹤0.01% 1597
2022
Q1 		$18K Sell
1,900
-6,240
-77% -$72.2K ﹤0.01% 1256
2021
Q4 		$155K Buy
8,140
+2,100
+35% +$54.5K 0.01% 764
2021
Q3 		$201K Buy
6,040
+2,768
+85% +$85.6K 0.01% 653
2021
Q2 		$127K Buy
3,272
+1,972
+152% +$77.4K 0.01% 778
2021
Q1 		$63K Buy
1,300
+1,000
+333% +$48K ﹤0.01% 946
2020
Q4 		$16K Sell
300
-200
-40% -$6.76K ﹤0.01% 1193
2020
Q3 		$13K Sell
500
-500
-50% -$11.5K ﹤0.01% 1215
2020
Q2 		$19K Hold
1,000
– – ﹤0.01% 1151
2020
Q1 		$10K Buy
+1,000
New +$12.6K ﹤0.01% 1259

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Benjamin F. Edwards & Company's TGTX Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its TG Therapeutics (TGTX) position steady in Q2 2024 at 900 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #1597.

Benjamin F. Edwards & Company first reported a position in TGTX in Q1 2020 and has held it in 18 quarters since. The position peaked at $201K in Q3 2021. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Benjamin F. Edwards & Company held 900 shares of TG Therapeutics worth $16K as of Q2 2024.
  • Benjamin F. Edwards & Company left its TG Therapeutics share count unchanged in Q2 2024.
  • TG Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1597 holding.
  • Benjamin F. Edwards & Company first reported a position in TG Therapeutics in Q1 2020 and has held it in 18 quarters since.
  • Benjamin F. Edwards & Company's TG Therapeutics position peaked at $201K in Q3 2021.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.